114 related articles for article (PubMed ID: 38719543)
1. CCR5 and CCL5 in metastatic colorectal cancer.
Schlechter BL; Stebbing J
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38719543
[TBL] [Abstract][Full Text] [Related]
2.
Battaglin F; Baca Y; Millstein J; Yang Y; Xiu J; Arai H; Wang J; Ou FS; Innocenti F; Mumenthaler SM; Jayachandran P; Kawanishi N; Lenz A; Soni S; Algaze S; Zhang W; Khoukaz T; Roussos Torres E; Seeber A; Abraham JP; Lou E; Philip PA; Weinberg BA; Shields AF; Goldberg RM; Marshall JL; Venook AP; Korn WM; Lenz HJ
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212126
[TBL] [Abstract][Full Text] [Related]
3. Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial.
Suenaga M; Stintzing S; Cao S; Zhang W; Yang D; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Schirripa M; Soni S; Barzi A; Heinemann V; Lenz HJ
Eur J Cancer; 2019 Jan; 107():100-114. PubMed ID: 30554073
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression via CCR5.
Nishikawa G; Kawada K; Nakagawa J; Toda K; Ogawa R; Inamoto S; Mizuno R; Itatani Y; Sakai Y
Cell Death Dis; 2019 Mar; 10(4):264. PubMed ID: 30890699
[TBL] [Abstract][Full Text] [Related]
5. Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients.
Suenaga M; Cao S; Zhang W; Yang D; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Schirripa M; Soni S; Barzi A; Yamaguchi T; Lenz HJ
Int J Cancer; 2019 May; 144(10):2567-2577. PubMed ID: 30411783
[TBL] [Abstract][Full Text] [Related]
6. Tumor bud-derived CCL5 recruits fibroblasts and promotes colorectal cancer progression via CCR5-SLC25A24 signaling.
Gao LF; Zhong Y; Long T; Wang X; Zhu JX; Wang XY; Hu ZY; Li ZG
J Exp Clin Cancer Res; 2022 Mar; 41(1):81. PubMed ID: 35241150
[TBL] [Abstract][Full Text] [Related]
7. CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment.
Wang SW; Liu SC; Sun HL; Huang TY; Chan CH; Yang CY; Yeh HI; Huang YL; Chou WY; Lin YM; Tang CH
Carcinogenesis; 2015 Jan; 36(1):104-14. PubMed ID: 25330803
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.
Aldinucci D; Casagrande N
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772686
[TBL] [Abstract][Full Text] [Related]
9. Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.
Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Ning Y; Cremolini C; Antoniotti C; Borelli B; Mashima T; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Lonardi S; Yamaguchi T; Falcone A; Loupakis F; Lenz HJ
Clin Colorectal Cancer; 2018 Jun; 17(2):e395-e414. PubMed ID: 29606345
[TBL] [Abstract][Full Text] [Related]
10. CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRβ in colorectal carcinoma.
Cambien B; Richard-Fiardo P; Karimdjee BF; Martini V; Ferrua B; Pitard B; Schmid-Antomarchi H; Schmid-Alliana A
PLoS One; 2011; 6(12):e28842. PubMed ID: 22205974
[TBL] [Abstract][Full Text] [Related]
11.
Battaglin F; Ou FS; Qu X; Hochster HS; Niedzwiecki D; Goldberg RM; Mayer RJ; Ashouri K; Zemla TJ; Blanke CD; Venook AP; Kabbarah O; Lenz HJ; Innocenti F
J Clin Oncol; 2024 Jun; 42(16):1890-1902. PubMed ID: 38457761
[TBL] [Abstract][Full Text] [Related]
12. CCL5-deficiency enhances intratumoral infiltration of CD8
Zhang S; Zhong M; Wang C; Xu Y; Gao WQ; Zhang Y
Cell Death Dis; 2018 Jul; 9(7):766. PubMed ID: 29991744
[TBL] [Abstract][Full Text] [Related]
13. The potential to target CCL5/CCR5 in breast cancer.
Velasco-Velázquez M; Xolalpa W; Pestell RG
Expert Opin Ther Targets; 2014 Nov; 18(11):1265-75. PubMed ID: 25256399
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral density of regulatory T cells is a predictor of host immune response and chemotherapy response in colorectal cancer.
Oshi M; Sarkar J; Wu R; Tokumaru Y; Yan L; Nakagawa K; Ishibe A; Matsuyama R; Endo I; Takabe K
Am J Cancer Res; 2022; 12(2):490-503. PubMed ID: 35261782
[TBL] [Abstract][Full Text] [Related]
15. CCL5/CCR5 axis promotes the motility of human oral cancer cells.
Chuang JY; Yang WH; Chen HT; Huang CY; Tan TW; Lin YT; Hsu CJ; Fong YC; Tang CH
J Cell Physiol; 2009 Aug; 220(2):418-26. PubMed ID: 19334035
[TBL] [Abstract][Full Text] [Related]
16. Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
Lenz HJ; Ou FS; Venook AP; Hochster HS; Niedzwiecki D; Goldberg RM; Mayer RJ; Bertagnolli MM; Blanke CD; Zemla T; Qu X; Wirapati P; Tejpar S; Innocenti F; Kabbarah O
J Clin Oncol; 2019 Aug; 37(22):1876-1885. PubMed ID: 31042420
[TBL] [Abstract][Full Text] [Related]
17. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
[TBL] [Abstract][Full Text] [Related]
18. Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients.
Suenaga M; Zhang WU; Mashima T; Schirripa M; Cao S; Okazaki S; Berger MD; Miyamoto Y; Barzi A; Yamaguchi T; Lenz HJ
Cancer Genomics Proteomics; 2021; 18(3):317-324. PubMed ID: 33893084
[TBL] [Abstract][Full Text] [Related]
19. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells.
Chang LY; Lin YC; Mahalingam J; Huang CT; Chen TW; Kang CW; Peng HM; Chu YY; Chiang JM; Dutta A; Day YJ; Chen TC; Yeh CT; Lin CY
Cancer Res; 2012 Mar; 72(5):1092-102. PubMed ID: 22282655
[TBL] [Abstract][Full Text] [Related]
20. Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration.
Zumwalt TJ; Arnold M; Goel A; Boland CR
Oncotarget; 2015 Feb; 6(5):2981-91. PubMed ID: 25671296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
